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AbstrAct
Aim. Excessive activation and platelet aggregation play important roles in the aetiopathogenesis of cerebral ischaemia. The aim 
of this study was to assess the relationship between platelet reactivity, gender and vascular risk factors in cerebral ischaemia 
patients.
clinical rationale for the study. The research is useful because we found high risk groups of inefficient aspirin treatment in 
cerebral ischaemia patients.
Material and methods. The study involved 101 patients, including 69 patients with ischaemic stroke and 32 patients with 
transient ischaemic attack. The assessment of platelet reactivity was made within 24 hours of the disease onset using two 
aggregometric methods: impedance and optical. 
results. Resistance to acetylsalicylic acid among people with cerebral ischaemia was estimated at 30.69% using impedance 
aggregometry and 9.2% using optical aggregometry. There were no differences in platelet reactivity or ASA resistance between 
the groups of patients with stroke and TIA in either method. In the whole group of patients (p = 0.04), and in the group of pa-
tients with stroke (p = 0.0143), higher reactivity of platelets was observed by impedance aggregometry in men than in women. 
In the whole group of patients (p = 0.0229), and in the subgroup with stroke (p = 0.0123), it was shown that aspirin resistance is 
significantly more common in the subgroup of men than in women. In patients suffering from nicotine addiction, significantly 
higher platelet reactivity was found in the whole group of patients (p = 0.004), as well as in the subgroup of patients with stroke 
(p = 0.0135).
conclusions. There are no differences between platelet reactivity and the incidence of aspirin resistance in patients with stroke 
and TIA. Male gender and smoking are associated with greater reactivity of platelets and more frequent occurrence of acetylsa-
licylic acid resistance in patients with cerebral ischaemia.
clinical implications. Dual antiplatelet therapy or clopidogrel treatment should be considered in smoking males with cerebral 
ischaemia due to the high risk of aspirin inefficiency.
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Introduction
Stroke is a crucial social and medical problem of the 21st 
century, and one of the main causes of morbidity and long-
term disability. It is also the second most frequent cause of 
death in the world [1]. In 2013 the American Heart Asso-
ciation/American Stroke Association (AHA/ASA) proposed 
a new definition of ischaemic stroke as an episode of sudden 
neurological disorder caused by focal cerebral, spinal cord 
or retinal ischaemia persisting over 24 hours or correspond-
ing to the morphological features of central nervous system 
ischaemia. Thus, due to such an updated definition, ischaemic 
stroke can also be diagnosed when clinical symptoms last less 
than 24 hours but where neuroimaging studies have demon-
strated an ischaemic infarction, as well as in thrombolytic pa-
tients whose symptoms of focal deficit have undergone a rapid 
regression [2]. If the time and radiology criteria are not met, 
transient ischaemic attack (TIA) is diagnosed. 
Platelet activation plays an important role in the 
pathomechanism of ischaemic stroke, especially in the 
thrombotic mechanism. Antiplatelet therapy, by inhibiting the 
activation and aggregation of platelets, is the current standard 
of pharmacological treatment, both in the treatment of the 
acute phase and in the prophylactic treatment of secondary 
ischaemic stroke [3]. Both European and American standards 
recommend several antiplatelet drugs with similar efficacy, but 
acetylsalicylic acid (ASA) is still the most commonly used. 
Unfortunately, a phenomenon that limits the effectiveness of 
ASA is the so-called resistance to acetylsalicylic acid [4]. In 
order to optimise antiplatelet therapy, tests evaluating platelet 
function-platelet reactivity are used, and these form the basis 
for the diagnosis of laboratory resistance. Obtaining high 
values of platelet reactivity indicates a weak therapeutic effect 
on the anti-aggregation drug [5].
Previous reports in the literature regarding the occurrence 
and importance of aspirin resistance in patients with cere-
bral ischaemia are scarce and have had inconclusive results. 
Therefore, the aim of this study was to assess the relationship 
between platelet reactivity, vascular risk factors and gender in 
patients with cerebral ischaemia.
Clinical rationale for the study
The results of this study will be clinically useful, because 
we found high risk groups of aspirin treatment inefficiency in 
patients with cerebral ischaemia and were able to offer them 
a different, more effective, prophylaxis.
Material and methods
Research population
The study was conducted between February and December 
2016 in the Department of Neurology at the University Hospital 
No. 1 in Bydgoszcz. The prospective study included 69 patients 
who met the criteria for the diagnosis of ischaemic stroke 
and 32 patents with TIA. On admission oral treatment with 
acetylsalicylic acid (ASA) at a dose of 150 mg was commenced 
in all patients. The following exclusion criteria were used: lack 
of patient consent to participate in the study, or inability to 
express it consciously (e.g. stroke with aphasia or quantitative 
disturbances of consciousness), patients with embolic cerebral 
ischaemia (with documented atrial fibrillation, thrombus in 
the heart cavities or dilated cardiomyopathy), patients with 
oncological history, patients who had taken ASA before 
admission, patients with chronic inflammatory processes 
that may affect the objective assessment of platelet function, 
e.g. with chronic venous thrombosis of the lower limbs or 
chronic lower limb ischaemia, patients who had had a stroke 
or TIA during the previous two years, patients with significant 
bleeding in the last two years, e.g. gastrointestinal bleeding, 
thrombocytopenia < 100,000/ul, level of haemoglobin <9 g/
dL, value of haematocrit < 35%. The general characteristics 
of the studied population and a comparison between the 
group of patients with stroke and those with TIA are set out 
in Table 1. The study protocol was approved by the Bioethics 
Committee of Nicolaus Copernicus University in Torun at 
Collegium Medicum of Ludwik Rydygier in Bydgoszcz (KB 
number 73/2016). This study included only patients who, 
having read the study protocol, signed informed consent to 
participate in the study.
Platelet reactivity research
The study of platelet reactivity was performed by 
optical aggregometry and impedance aggregometry in the 
Laboratory of Biotechnology of the Chair of Pharmacology 
and Therapy at Collegium Medicum in Bydgoszcz of UMK in 
Torun. Patients’ blood tests to assess platelet reactivity were 
performed at a similar time of day (10am–12noon) within 
24 hours of stroke symptoms onset. The optical aggregometry 
(LTA, light transmission aggregometry) test was performed 
using a Chrono-Log aggregometer (Havertown, PA, USA). 
Arachidonic acid was used as the agonist. The aggregometer 
analysed changes in transmitted light in percentages, with 0% 
being the maximum optical density of platelet rich plasma 
and 100% a complete lack of plasma optical density. Then, the 
signal was automatically converted to area under the curve 
(AUC) units — as the final result of the determination. An 
average increase in absorbance of more than 20% (or AUC > 
115) was considered to be resistance to ASA that is equivalent 
to that of ‘high’ on aspirin treatment platelet reactivity induced 
by arachidonic acid. The test was performed according to the 
standard protocol [6]. The evaluation of optical aggregometry 
was performed in 65 of the 101 subjects, due to an aggregometer 
failure that could not be repaired during the study.
The study of platelet function by impedance aggregometry 
was performed using a Multiplate- Dynabyte multi-channel 
platelet function analyser (Roche Diagnostics, France). The 
study used the so-called ASPI test, i.e. aggregation dependent on 
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     P-values
Age median (range)* 67 (40–89) 70 (49–90) 0.1556
Male N, (%)** 35 (50.7%) 13 (40.6%) 0.3444
Hypertension N, (%)** 61 (88.4%) 26  (81.25%) 0.3628
Diabetes N, (%)** 25 (36.3%) 11 (34.3%) 1.0
Hyperlipidemia N, (%)** 28 (40.6%) 17 (53.12%) 0.2846
Smoking N, (%)** 24 (34.8%) 6 (18.75%) 0.1593
Ischaemic heart disease N, (%)** 9 (13.0%) 4  (12.5%) 1.0
Obesity N, (%)** 48 (69.5%) 22 (68.75%) 0.7675
CRP [mg/L] Median (range)* 4.79 (0.36–30.45) 1.835 (0.21–15.2) 0.5157
HBA1c [%] Median, (range)* 318  (59–590) 292.5 (168–469) 0.1864
Homocystein [µmol/L] Median (range)* 5,7  (5–10.04) 5.8  (4.2–7.5) 0.2713
Fibrinogen [mg/dL] Median (range)* 10.78  (3.52–48.6) 9.75 (5.88–18) 0.3524
*Mann-Whitney U-test; ** Chi2 calculation
cyclooxygenase — using arachidonic acid as a platelet activator. 
Aggregation results were obtained after another 6 minutes for 
each test as an average of two measurements in the form of 
a curve, on the basis of which the area under the curve (AUC) 
was determined. The AUC parameter was reported as the final 
result of the determination. Those patients with results above 
40 AUC were considered to be ASA resistant, that is equivalent 
to ‘high’ on aspirin treatment platelet reactivity induced by 
arachidonic acid. Patients with AUC values under 30 were 
treated as sensitive to ASA, and those measured as being from 
30 to 40 as mildly sensitive to ASA. The test was performed 
according to the standard protocol [7]. The evaluation of 
impedance aggregometry was performed in all 101 subjects.
Statistical evaluation methods
The statistical analysis of collected data was performed 
with the help of STATISTICA statistical program — version 
13.1, Dell. Compatibility with normal distribution was tested 
with the Shapiro-Wilk test and homogeneity of variance with 
the Levene test. Due to the incompatibility of the distribution 
of features with the normal distribution and the lack of 
homogeneity of variance in the analysis, non-parametric tests 
were used — U Mann–Whitney test (assessment of the 
relation between binary and continuous variables), Spearman’s 
rank correlation test (evaluation of the relations between 
variables), and chi-square independence test (evaluation of 
relations between categorised variables). A significance level of 
p < 0.05 was considered statistically significant.
Results
Assessment of platelet reactivity
The assessment of platelet reactivity with LTA was per-
formed in 65 patients: in the group of 43 stroke patients, the 
median was 8.8 AUC (min. 0 AUC, max. 208.6 AUC), while 
in 22 TIA patients the median was 8.25 AUC (min. 0.2 AUC, 
max. 278 AUC). There was no statistically significant differ-
ence in platelet reactivity between the study group of stroke 
patients and the TIA group (p = 0.9558). The incidence of 
aspirin resistance in all patients was 9.2%.
Evaluation of platelet reactivity with the Multiplate sys-
tem was performed in 101 patients. The median of platelet 
reactivity in the whole group was 27 AUC (min. 6 AUC, 
max. 108 AUC). In the group of stroke patients, the median 
was 29 AUC (min. 6 AUC, max. 108 AUC), while in the TIA 
group the median was 24 AUC (min. 7 AUC, max. 108 AUC). 
There were no statistically significant differences in platelet 
reactivity between the study group of stroke patients and the 
TIA group (p = 0.8667). Using the criterion of ASA resistance 
to the ASA-resistant group (AUC > 40), 31 patients were in-
cluded, 16 patients were included into the group with medium 
ASA-sensitivity (30 ≤ AUC ≤ 40), and 54 to the ASA-sensitive 
group (AUC < 30). The distribution of the occurrence of as-
pirin resistance in patients with stroke and TIA did not differ 
in a statistically significant way (Chi2 NW = 0.17; p = 0.9185) 
(Fig. 1). The incidence of resistance to ASA in the Multiplate 
study was 30.69% in all patients with ischaemia of the brain; 
in the subgroup of patients with stroke it was 31.9%, and in 
the subgroup with TIA it was 28.1%.
Platelet reactivity and anthropometric  
parameters
There was no significant correlation between the age of 
the patients and platelet reactivity assessed with the Multiplate 
or the LTA method (R = -0.1499, p = 0.3451 for Multiplate 
and R = 0.05 and p = 0.6585 for LTA). In the whole group of 
subjects, statistically higher platelet reactivity was assessed by 
means of the Multiplate test in men than in women (median, 
respectively: 34.5 vs 23 AUC; p = 0.04) (Fig. 2). A similar dif-
ference was also found in the subgroup of patients with stroke 
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Figure 1. Distribution of the occurrence of aspirin resistance in 
patients with stroke and TIA
Figure 2. Comparison of platelet reactivity by impedance aggrego-
metry (in AUC-units) in men and women with cerebral ischaemia
(median, respectively: 40 vs 23.5 AUC, p = 0.0143). In the 
subgroup of patients with TIA, similar relationships were not 
demonstrated (p = 0.7443). There was no relationship between 
platelet reactivity assessed by the LTA test and patient gender 
(in the whole group p = 0.6841, in the subgroup with stroke 
p = 0.6270, in the subgroup with TIA p = 0.8030). In the whole 
group of patients, it was demonstrated that aspirin resistance 
was significantly more common in the subgroup of men than 
in women (Chi2 NW = 5.18; p = 0.0229) (Fig. 3). A similar 
relationship, statistically significant, was noted in the subgroup 
of patients with stroke (Chi2 NW = 6.26; p=0.0123). In the 
subgroup of patients with TIA, there were no such relation-
ships (Chi2 NW = 0.08; p = 0.78).
Platelet reactivity and risk factors for vascular 
disease
In patients suffering from nicotine addiction, significantly 
higher platelet reactivity was found, assessed by the Multiplate 































Figure 3. Occurrence of ASA resistance in men and women with 
cerebral ischaemia
Figure 4. Comparison of platelet reactivity by impedance aggre-
gometry (in AUC-units) in smoking and non-smoking patients with 
cerebral ischaemia
as well as in the subgroup of patients with stroke (p = 0.0135) 
There was no effect of smoking on the platelet reactivity as-
sessed by LTA. Other risk factors for vascular disease did not 
have a significant impact on platelet reactivity, as assessed by 
the Multiplate method (Tab. 2) and the LTA method. In the 
group of patients with ischaemic stroke burdened with nico-
tine addiction, there was a significantly higher proportion of 
ASA-resistant patients compared to non-smokers (Chi2 NW 
= 10.1592; p = 0.0014) (Fig. 5).
Discussion
The evaluation of the impact of recognised risk factors for 
vascular disease on platelet reactivity has been the subject of 
many studies and publications. Independent authors have not 
shown, in their studies, a relationship between the occurrence 
of hypertension, diabetes, hyperlipidaemia or ischaemic heart 
disease and the level of platelet reactivity, using various meth-
ods of assessing platelet function [8–12]. Only El-Mitwalli et 
al. [13] reported that hyperlipidaemia is more common in an 
ASA-resistant group. In this study, a significant relationship 
between platelet reactivity and hypertension, coronary artery 
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disease, diabetes and hyperlipidaemia was also not shown, 
which coincides with the observations of most authors. 
The risk factor that significantly differentiated the reac-
tivity of platelets in this study was nicotine addiction. Active 
tobacco smokers were characterised by a higher median 
platelet reactivity than non-smokers. In addition, the incidence 
of nicotine addiction in the group of patients with cerebral 
ischaemia in the ASA-resistant group was significantly higher 
than in the ASA-sensitive group. Zheng et al. [12] also showed 
in their study that nicotine addiction is more common in 
patients with stroke in the ASA-resistant patients than those 
sensitive to ASA (p = 0.02); similar relationships were noted 
by El-Mitwalli et al. Other authors have not found a relation-
ship between nicotine addiction and platelet reactivity or 
ASA resistance in patients with ischaemic stroke [8–11,14]. 
Smoking affects the functions of platelets in a multifactorial 
manner. Nicotine addiction intensifies platelet aggregation, 
and also reduces their sensitivity to exogenous NO (nitric 
oxide), thereby increasing their adhesion and activation [15]. 
Smoking three cigarettes quickly in a row increases the ADP-
dependent platelet aggregation in vitro. Smoking also activates 
the expression of P-selectin on the surface of platelets and its 
serum level, which stimulates platelet activation. In addition, 
regardless of the mechanisms leading to the modification of 
platelet function, smoking cigarettes increases blood viscosity, 
the activity of coagulation processes, fibrinogen levels and 
blood pressure, and reduces cerebral blood flow through 
vasospasm. Nicotine addiction raises the risk of stroke on 
average by 1.5–3 times [16]. All patients after stroke or TIA are 
advised to stop smoking, including avoiding passive smoking. 
With regard to the results of this work, this recommenda-
tion proves to be a necessary requirement to obtain effective 
antiplatelet therapy. The American and European guidelines 
do not give information about the routine determination of 
platelet reactivity which points to a lack of antiplatelet therapy 
modifications in smokers. It is worth mentioning the work of 
Blache et al. [17] who showed that the increased reactivity of 
platelets is reduced to optimal limits only by a dose of 650 mg 
ASA. It is also worth noting the results of the work of Rollini 
et al. [18] who assessed platelet reactivity in patients with 
advanced atherosclerosis, who were taking ASA, and who 
were additionally given clopidogrel at a dose of 75 mg for 
7–10 days, who then repeated platelet reactivity assessment. 
In the group of the greatest smokers, a significant decrease in 
platelet reactivity was achieved. 
The presented results may suggest the necessity to adjust 
the doses of antiplatelet drugs in patients with nicotine ad-
diction, the replacement of ASA with clopidogrel in patients 
with recurrent stroke, and even the consideration of dual 
antiplatelet therapy in smokers.
The results of the study showed higher platelet reactivity 
and a higher incidence of aspirin resistance in men compared 
to the whole group of subjects and compared to patients with 
stroke. Similar conclusions were drawn by Jaremo et al. [19], 
who in a population of men with ischaemic stroke had higher 
platelet activation assessed by the method of flow cytometry. 
However, the relation between platelet reactivity and gender 
remains debatable due to the fact that most other researchers 
have not shown any relationship between platelet reactivity 
and aspirin resistance in populations of patients with stroke 
[8, 9, 12, 20, 21]. 
In the analysis presented in this study, the groups of pa-
tients with stroke and TIA did not differ in terms of gender 
or platelet reactivity. Considering the abovementioned fact, 
the demonstration of a significant dependence of platelet 
Table 2. Comparison of platelet reactivity assessed by the Multiplate method (in AUC-units) in subgroups of patients with stroke with and without current 
given risk factor
risk factor   Multiplate P-values
risk factor present 
 Median (range)
risk factor absent  
Median (range)
Hypertension 24.5 (6–87) AUC 29 (9–108) AUC 0.7800
Diabetes 29 (6–108) AUC 27 (9–79) AUC 0.6521
Hyperlipidemia 28 (6–87) AUC 30.5 (9–108) AUC 0.7848
Ischaemic heart disease 30 (6–108) AUC 17 (6–69) AUC 0.1077
Smoking 24 (6–108) AUC 40.5 (10–87) AUC 0.0135
Obesity 40 (6–87) AUC 27 (9–108) AUC 0.2420
Non-
-smoking


















Figure 5. Occurrence of ASA resistance in subgroups of patients 
with cerebral ischaemia withand without nicotine addiction
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reactivity on gender in the whole group, and especially the 
significant gender relationship in the subgroup of patients 
with stroke, emphasises that male gender is an independent 
platelet activating factor in stroke patients. The explanation 
of the dependence of platelet activity on gender may be 
the hormonal basis, as it has been shown that testosterone 
increases platelet aggregation, while oestrogens and proges-
terone inhibit platelet aggregation [22, 23]. Greater platelet 
reactivity in the male gender may also partly explain why the 
incidence of stroke is lower in women and why stroke occurs 
in women at a later age [24, 25]. On the other hand, taking 
into account the greater aspirin resistance in the group of 
men noted in this study, women are also better beneficiaries 
of antiplatelet therapy than men, in whom greater resistance 
to ASA may result in a less effective anti-aggregatory effect of 
the drug. Similar observations were made by Becker et al. [26] 
who in their study showed that small doses of ASA (81 mg) 
more effectively inhibit platelet aggregation in women than 
in men, which corresponds to lower platelet reactivity found 
in women in the LTA and PFA (Platelet Function Assay) 
method — 100 after the ASA therapy. Although in the above 
study only healthy volunteers from a group at increased risk 
of cardiovascular incidents were evaluated, not a population 
of patients with stroke, its results may indirectly confirm the 
relationship between aspiring resistance and gender indicated 
in this study.
The current study has its limitations. The number of the 
studied population is moderate, but proved to be sufficient to 
formulate conclusions. Most conclusions were based only on 
the results of platelet reactivity by impedance aggregometry 
(Multiplate). The conclusions based only on one, poorly 
standardised, method, with agreed resistance criteria, should 
be approached with caution [27]. 
However, the authors consider the one-time assessment 
of platelet function to be the greatest limitation of their 
analysis, which was performed at different times after the 
onset of stroke symptoms within the first 24 hours and 
at different times from taking the dose of acetylsalicylic 
acid. It seems that an assessment of platelet function only 
in a single measurement may be insufficient to properly 
assess the effect of ASA resistance. Taking into account the 
data from the literature, the authors are of the opinion that 
only the sequential determination of platelet reactivity on 
successive days of stroke seems to be most optimal for the 
characterisation of aspirin resistance phenomenon [9, 21, 28]. 
Another limitation is the fact that laboratory resistance does 
not always correlate with clinical resistance [29, 30].
Conclusions
1. The prevalence of aspirin resistance in the group of patients 
with cerebral ischaemia is estimated at 30.69% in impe-
dance aggregometry and 9.2% in optical aggregometry.
2. There are no differences between platelet reactivity and 
the incidence of aspirin resistance in patients with stroke 
and TIA. 
3. Male gender and smoking are associated with greater 
reactivity of platelets, and more frequent occurrence of 
aspirin resistance, in patients with cerebral ischaemia.
Clinical implications
On the basis of this study it could be considered optional 
treatment in smoking males with cerebral ischaemia because 
of the high risk of aspirin inefficiency. A higher dose of aspirin, 
dual antiplatelet therapy, or clopidogrel treatment could be 
taken for this purpose, while bearing in mind the increased 
risk of bleeding complications. In smoking males, routine 
determination of platelet reactivity for evaluation of aspirin 
resistance should be considered, although this is still not 
available in many countries. Further studies on this subject 
are needed to confirm our observations.
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